Measurement of physical activity in cancer survivors: a validity study

J Cancer Surviv. 2014 Jun;8(2):205-12. doi: 10.1007/s11764-013-0325-3. Epub 2013 Dec 7.

Abstract

Purpose: The purpose of the study was to validate the Taiwanese version of the Physical Activity Scale for the Elderly (PASE-T) and to assess physical activity in Taiwanese cancer survivors.

Methods: One hundred twenty-seven cancer survivors participated in this study. Instruments consisted of the PASE-T, the Taiwanese version of the MD Anderson Symptom Inventory (MDASI-T), Karnofsky performance status (KPS), and actigraph. Reliability was assessed by calculating the test-retest reliability. The validity was assessed by the content validity, criterion-related validity, convergent validity, and known-group validity.

Results: The test-retest reliability of PASE-T was 0.90 over a 2-week interval, based on a sample of 30 patients. The content validity index was very acceptable at 0.91. Convergent validity was demonstrated by its significant association with MDASI-T scores (symptom severity: r = -0.23, p = 0.001; symptom interference: r = -0.21, p = 0.001) and KPS scores (r = 0.59, p < 0.001). Criterion-related validity was established by a significant relationship to the actigraph total counts per minute (r = 0.64, p < 0.001). Known-group validity was established by its ability to detect significant differences according to a patient's performance status. Moreover, KPS (β = 0.37), fatigue (β = -0.32), and age (β = -0.20) were significant predictors of physical activity (R(2) = 0.46).

Conclusions: The PASE-T is a reliable and valid instrument for measurement of physical activity among cancer survivors in Taiwan.

Implication for cancer survivors: This scale could be a useful measure of physical activity in cancer survivors and subsequently facilitate the quality of oncology care.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Adult
  • Aged
  • Female
  • Humans
  • Male
  • Middle Aged
  • Motor Activity*
  • Neoplasms / mortality*
  • Neoplasms / physiopathology
  • Survivors*